Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Results and discussion br Conclusion In
2021-05-07

Results and discussion Conclusion In the current study, a series of novel ‘open-chain’ classes of E. coli PDHc E1 inhibitors, N-acylhydrazone pyrimidine derivatives A, B, and C were designed and synthesized. As novel ThDP analogs, all A displayed moderate to powerful inhibitory activity with I
-
br Authors contribution br Disclosure statement br
2021-05-07

Authors contribution Disclosure statement Acknowledgements This study has received funding from the Italian Ministry of University and Research (PRIN 2015, grant number 2015373Z39_008) and from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115797 (INNODIA)
-
To investigate the role of DPP inhibition in
2021-05-07

To investigate the role of DPP-4 inhibition in inflammation-induced bone resorption, we evaluated the effect of a DPP-4 inhibitor on LPS-induced osteoclast formation and bone-resorption in vivo. Our results showed that the DPP-4 inhibitor inhibited LPS-induced osteoclast formation and bone resorptio
-
Everolimus treatment showed an increase in
2021-05-07

Everolimus treatment showed an increase in the number of plaques and a reduction in plaque size, depending on concentration and treatment time (Fig. 1, Fig. 2). Everolimus-pretreated Ac-DEVD-pNA adsorbed less virus with more plaque formation in the initial phase of infection (Fig. 3). The ability an
-
The absorption rate of polyphenols into the body is usually
2021-05-06

The 98 2 synthesis rate of polyphenols into the body is usually low. For example, the absorption rate of epigallocatechin gallate (EGCG), an active component in GP, is approximately 1% (Chen et al., 1997). To increase absorption of GP in the body, people have been increasing their intake of functio
-
br Conflict of interest br Acknowledgments Part of this work
2021-05-06

Conflict of interest Acknowledgments Part of this work was supported by Institut Francais en Egypte, and the Academy of Scientific Research and Technology in Egypt under the frame of “Imhotep Project N°: 31681XL” and “STDF/IFE project N° 30630″ Introduction NSAIDs play an important role in
-
Unlike many forms of SNHL
2021-05-06

Unlike many forms of SNHL, cCMV may be treatable. The antiviral drug valganciclovir (VGCV) has been proposed to improve hearing, speech, and language outcomes associated with this infection [6]. A recent publication from the CASG (Collaborative Antiviral Study Group) reported that a six-month course
-
br torsion is a urological emergency that may occur
2021-05-06

torsion is a urological emergency that may occur at any age. To establish blood flow surgical detorsion is required in most cases while detorsion can sometimes be achieved by hand assistance. Regardless of the correction method 2 phases (I/R) negatively affect germ cells. The torsion phase decreas
-
EPAC activation in VSMCs and ECs
2021-05-06

EPAC activation in VSMCs and ECs reverses several processes involved in the development of in-stent restenosis. Of particular relevance is the ability of EPAC1 to induce SOCS3 gene expression, as SOCS3 exerts multiple protective effects in both cell types, while immunohistochemical studies have show
-
Based upon these findings on portions A
2021-05-06

Based upon these findings on portions A and B, novel scaffolds of EP4 antagonist, and (R & R=()-Me; =Cl; R=H), shown in , were identified. We next focused on optimizing portion C of these scaffolds. We utilized for an alternative synthesis of nicotinamide scaffold , which is quite effective for
-
After activation AKT phosphorylates target proteins involved
2021-05-06

After activation, AKT phosphorylates target proteins involved in cell growth, metabolism and survival (Manning and Cantley, 2007). For example, AKT phosphorylates the pro-apoptotic protein BAD, preventing it from binding to and inactivating Bcl-xL in mitochondria (Datta et al., 1997). In turn, Bcl-x
-
OxLDL down regulates eNOS and
2021-05-06

OxLDL down-regulates eNOS and up-regulates iNOS, thereby augmenting the formation of NO and protein S-nitrosylation in human endothelial papain [26]. Importantly, iNOS-mediated S-nitrosylation plays an increasingly significant role in cardiovascular diseases [34]. For example, iNOS-mediated IRE1α S
-
br Acknowledgments This work was supported by R gion
2021-05-06

Acknowledgments This work was supported by Région Auvergne “Nouveau chercheur”. This study has been performed with the assistance of Christelle Damon-Soubeyrand for histology technical assistance using “Anipath” Platform (GReD) and Sandrine Plantade, Keredine Ouchen and Philippe Mazuel for animal
-
br Concluding Remarks Recent studies
2021-05-06

Concluding Remarks Recent studies have provided unprecedented details of APC/C structure and enzymology, which explain how the activity of this massive E3 ligase is controlled, and how ubiquitylation is achieved to temporally regulate cell division. Although one pervasive question has been why th
-
The BMP family comprises significant growth factors for
2021-05-06

The BMP family comprises significant growth factors for the regeneration of bone and cartilage. Among these, BMP- has been known as an early marker during the proliferation of osteoblast cells, and one of the most potent stimulators of osteoblastic cells differentiation [40]. Studies with COX-2 knoc
16311 records 666/1088 page Previous Next First page 上5页 666667668669670 下5页 Last page